Clinical Trial Update: Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of MYOCET (doxorubicin liposome) in HER2-positive breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Myocet (liposomal doxorubicin)

Snippet

Sponsor: Cephalon, Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-02-23